Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BrainVectis

www.brainvectis.com

Latest From BrainVectis

Where Will CNS Drug Development Go In 2018?

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

Neurology Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • BrainVectis
  • Senior Management
  • Jerome Beqcourt, PhD, CEO
    Nathalie Cartier-Lacave, MD, CSO
    Sandro Alves, PhD, Dir., Preclinical Research
  • Contact Info
  • BrainVectis
    18 route du Panorama
    MIRCen – CEA
    Fontenay-aux-Roses, 92260
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register